Rubicon Research Private Limited

Ezra Pharma LLC

Other

Psm Healthcare Limited

Towa Pharmaceutical Europe, S.l. Unipersonal

Sun Pharmaceutical Advanced Research Centre Limited

Breckenridge Pharmaceutical, Inc.

Rubicon Research Pvt. Ltd.

Towa Pharmaceutical Europe S.l.

Pratibha Sudhir Pilgaonkar

Anilkumar Surendrakumar Gandhi

Maharukh Tehmasp Rustomjee

Joseph A Fix

Shirish A Shah

Paras Jain

Pradnya M Bagde

Atul A Kelkar

Nitin Bhalachandra Dharmadhikari

Rupali Kedar Suvarnapathaki

Ratnesh H Shrivastava

Jayant S Karajgi

Suma G Menon

Shivanand P Puthli

Varsha Barve

Vinderjit Sarjit Bhumra

Anilkumar S Gandhi

Paras R Jain

Pradnya Bagde

Hetal N Morvekar

Bagde; Pradnya M M

Compositions comprising a mixture of at least two types of particles wherein a) the first type of particles comprise dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates or hydrates thereof; and b) the second type of particles comprise at least one pharmaceutically acceptable organic acid, use of said compositions in the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and/or in the prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery and processes for the preparation of said compositions.

Oral pharmaceutical compositions of dabigatran etexilate

The present invention relates to gastroretentive formulations and to processes for preparation of the same. Particularly, the invention relates to gastroretentive dosage forms comprising at least one swelling agent and at least one swelling retardant.

Gastroretentive formulations

The present invention relates to oral care compositions and to method of maintaining oral health. The oral care composition of the present invention comprises at least one carbon dioxide source, at least one acid source, at least one abrasive and one or more pharmaceutically acceptable excipients.

Oral care compositions

The present invention provides a composition exhibiting delayed transit through the gastrointestinal tract comprising one or more active agents, fenugreek fiber and at least one pharmaceutically acceptable excipient. The present invention further relates to gastroretentive dosage forms comprising fenugreek fibers.

Compositions exhibiting delayed transit through the gastrointestinal tract

The present invention provides particulate delivery systems comprising plurality of particles comprising fenugreek gum and at least one pharmaceutically acceptable excipient. The particulate delivery systems of the present invention are used for the delivery of therapeutic, immunologic or diagnostic agents, and the like.

Particulate delivery systems

An excipient from-seeds and a process for preparation thereof is disclosed. The excipient obtained from-seeds, comprising insoluble and soluble dietary fibers can be used in various pharmaceutical or cosmetic compositions and food, nutritional or dietary preparations.

[object Object]

The present invention provides extended release pharmaceutical formulations of valsartan with controlled impurity levels. Particularly, the present invention provides extended release valsartan formulation which is substantially free of valsartan R-isomer impurity.

Extended release pharmaceutical formulations with controlled impurity levels

The present invention relates to stable solid formulations of vitamin Dand to processes for preparation of the same. The present invention provides stabilized compositions comprising vitamin Dat least one lipophilic dispersant, one or more antioxidants, at least one adsorbent and one or more pharmaceutically acceptable excipients and further coated with a barrier coating.

Stabilized vitamin D formulations

The present invention relates to coated extended release pharmaceutical formulations of valsartan comprising a core comprising valsartan and at least one coating layer over the core. The present invention further relates to extended release pharmaceutical formulations comprising (a) a core comprising valsartan and at least one hydrophilic swelling polymer and (b) at least one coating layer over the core wherein the coating layer in contact with the core is applied from an organic solvent based system.

Extended release pharmaceutical formulations

The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration.

Sustained release dosage form

A solvent free process of obtaining an insoluble fiber rich fraction from-seeds is disclosed. The multifunctional fiber rich fraction (FRF) and highly purified FRF are useful as excipients for pharmaceutical dosage forms for various routes of administration. These excipients can be used as binder, disintegrant, filler, dispersing agent, coating agent, film forming agent, thickener and the like, for preparation of variety of dosage forms. FRF and highly purified FRF can also be used in a controlled release, targeted release and other specialized delivery systems, as well as in food and cosmetics formulation.

Disclosed herein is a dispersible tablet composition including a pharmacologically active ingredient and at least one excipient that reduces the sedimentation rate of the active ingredient and a process for preparing the same.

Growing community of inventors

Mumbai, India

Pratibha Sudhir Pilgaonkar